Sermorelin
Also known as: GHRH(1-29), GRF 1-29 NH2, Sermorelin acetate
A synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). Directly stimulates the pituitary to produce and secrete GH.
Available from Nexis Labs
Sermorelin
Sizes: 10mg
From $79.99
Overview
Sermorelin is the biologically active fragment of endogenous GHRH, consisting of its first 29 amino acids. It is one of the earliest and most studied GHRH analogues, having been FDA-approved in the past for diagnostic testing of GH secretion in children. Because it works through the body's natural feedback mechanisms, it does not suppress the hypothalamic-pituitary axis in the way that exogenous GH administration can.
Research has examined sermorelin in contexts ranging from growth disorders in pediatric models to aging-related GH decline in elderly subjects. Its stimulation of endogenous GH preserves the pulsatile release pattern considered important for downstream IGF-1 production.
Mechanism of Action
Sermorelin binds directly to the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary, stimulating synthesis and secretion of endogenous growth hormone. Because it works upstream of GH itself, release remains subject to normal somatostatin feedback, preventing supraphysiological GH levels.
Research Areas
- ●GH deficiency diagnostics
- ●Age-related GH decline (somatopause) research
- ●Body composition and lean mass studies
- ●Bone mineral density investigation
- ●Sleep architecture and slow-wave sleep research
- ●Wound healing and tissue repair models
Storage & Handling
Store lyophilized powder at -20°C. Reconstituted: refrigerate at 2–8°C, use within 14–28 days.
Soluble in sterile or bacteriostatic water
For Research Use Only. This information is provided for educational and research purposes. Sermorelin is not approved for human consumption, veterinary use, or clinical application. All research must be conducted in accordance with applicable laws and institutional guidelines.